Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Fast-Tracked Psychedelic Medicines For Depression And PTSD

The Food and Drug Administration has fast-tracked three psychedelic medicines for review, issuing priority vouchers to companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone, a compound related to MDMA, for post-traumatic stress disorder, in a development that could put the first FDA-approved psychedelic medicines on the market as soon as this summer. The vouchers compress the agency’s standard review timeline from the usual 10 to 12 months down to just one to two months, a change the FDA Commissioner said is designed to ensure that red tape does not delay treatments that show genuine promise for conditions that have been notoriously difficult to treat. The three companies that received vouchers are Compass Pathways, the nonprofit Usona Institute, and Otsuka Pharmaceutical, which is acquiring the methylone program. The action followed an executive order signed by President Trump directing the FDA to prioritize psychedelic drugs that have received Breakthrough Therapy designation, a status reserved for treatments showing early evidence of substantial improvement over existing options.

For millions of Americans with treatment-resistant depression, PTSD, and other serious mental health conditions that have not responded to available medications, the move represents a potential turning point in access to a category of medicine that has shown significant clinical results but has remained largely inaccessible for decades. Psilocybin has shown durable antidepressant effects in multiple studies, with some patients maintaining improvement for at least a year after a single treatment course. The FDA also cleared the first-ever clinical study in the United States of noribogaine, a compound derived from the ibogaine plant, as a potential treatment for alcohol use disorder, a condition that affects more than 29 million Americans. The FDA Commissioner said the first psychedelic drug could receive approval by the end of summer, and that the field is moving forward grounded in sound science and rigorous clinical standards.

Source: https://edition.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers

PrevPreviousJurassic Park Star Sam Neill Is Cancer Free
NextBanksy Just Confirmed His Latest Masterpiece, And London Is Already Crowding Around ItNext

Recent Articles

Happy News

Eating Eggs Regularly May Cut Alzheimers Risk By Up To 27 Percent

May 9, 2026

A new study from Loma Linda University Health has found that adults 65 and older who eat eggs regularly have a significantly lower risk of developing Alzheimer’s disease, with people who consumed at least one egg per day for five or more days a week showing up to a 27

Read More
Happy News

Birdwatching Among Gen Z In Britain Has Grown By Over 1000 Percent Since 2018 And The Reasons Why Are Beautiful

May 8, 2026

Birdwatching has quietly become one of the fastest-growing hobbies among young people in Britain, with new research from the Royal Society for the Protection of Birds finding that nearly 750,000 people aged 16 to 29 now birdwatch regularly, a staggering increase of more than 1,000 percent since 2018. The study

Read More
Happy News

Meet The Record Holders Who Prove That Age Is Genuinely Just A Number

May 8, 2026

Guinness World Records has published a new feature celebrating some of the most extraordinary older athletes on the planet, a collection of record holders that makes a compelling case that age really is just a number. Leading the group is Mathea Allansmith of Hawaii, born in 1930, who took up

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.